Progress and potential of immune checkpoint blockade for treating advanced renal cell carcinoma

被引：0

作者：

Tykodi, Scott S. ^{[1
,2
]}

机构：

[1] Univ Washington, Dept Med, Div Med Oncol, Seattle, WA 98109 USA

[2] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA

来源：

IMMUNOTHERAPY | 2013年 / 5卷 / 06期

关键词：

CTLA-4; antigen; immune checkpoint; immunotherapy; LAG-3; PD-1; receptor; PD-L1; renal cell carcinoma; T lymphocyte; HIGH-DOSE INTERLEUKIN-2; INTERFERON-ALPHA; DOUBLE-BLIND; RECOMBINANT INTERLEUKIN-2; METASTATIC MELANOMA; T-CELLS; PHASE-I; CANCER; TRIAL; REGRESSION;

D O I：

10.2217/IMT.13.39

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Adaptive immune responses appear to influence the natural history of cancer progression, as well as therapeutic outcomes, in cancer patients. However, accumulating evidence suggests resistance mechanisms exploited by tumors may play a dominant role in limiting the effectiveness of T cell-mediated cancer therapies. Inhibitory coreceptors expressed by T lymphocytes, or so-called immune checkpoints, are now recognized to play critical roles in regulating the termination of adaptive immune responses. An overview of early-phase trial results distinguish blocking antibodies targeting inhibitory coreceptors as a highly promising approach to cancer immunotherapy for patients with advanced clear cell renal cell carcinoma. Prospects for advanced-phase clinical testing and novel therapy combinations with immune checkpoint blocking agents are discussed.

引用

页码：607 / 619

页数：13

共 66 条

[11] Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial [J].

Escudier, Bernard ;

Pluzanska, Anna ;

Koralewski, Piotr ;

Ravaud, Alain ;

Bracarda, Sergio ;

Szczylik, Cezary ;

Chevreau, Christine ;

Filipek, Marek ;

Melichar, Bohuslav ;

Bajetta, Emilio ;

Gorbunova, Vera ;

Bay, Jacques-Olivier ;

Bodrogi, Istvan ;

Jagiello-Gruszfeld, Agnieszka ;

Moore, Nicola .

LANCET, 2007, 370 (9605) :2103-2111

[12] Sorafenib in advanced clear-cell renal-cell carcinoma [J].

Escudier, Bernard ;

Eisen, Tim ;

Stadler, Walter M. ;

Szczylik, Cezary ;

Oudard, Stephane ;

Siebels, Michael ;

Negrier, Sylvie ;

Chevreau, Christine ;

Solska, Ewa ;

Desai, Apurva A. ;

Rolland, Frederic ;

Demkow, Tomasz ;

Hutson, Thomas E. ;

Gore, Martin ;

Freeman, Scott ;

Schwartz, Brian ;

Shan, Minghua ;

Simantov, Ronit ;

Bukowski, Ronald M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :125-134

[13] Multicenter, randomized, phase III trial of CD8+ tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma [J].

Figlin, RA ;

Thompson, JA ;

Bukowski, RM ;

Vogelzang, NJ ;

Novick, AC ;

Lange, P ;

Steinberg, GD ;

Belldegrun, AS .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) :2521-2529

[14]

Figlin RA, 2012, KIDNEY CANC J, V10, P10

[15] Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients [J].

Finke, James H. ;

Rini, Brian ;

Ireland, Joanna ;

Rayman, Patricia ;

Richmond, Amy ;

Golshayan, Ali ;

Wood, Laura ;

Elson, Paul ;

Garcia, Jorge ;

Dreicer, Robert ;

Bukowski, Ronald .

CLINICAL CANCER RESEARCH, 2008, 14 (20) :6674-6682

[16] RESULTS OF TREATMENT OF 255 PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA WHO RECEIVED HIGH-DOSE RECOMBINANT INTERLEUKIN-2 THERAPY [J].

FYFE, G ;

FISHER, RI ;

ROSENBERG, SA ;

SZNOL, M ;

PARKINSON, DR ;

LOUIE, AC .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (03) :688-696

[17] LAG-3 in Cancer Immunotherapy [J].

Goldberg, Monica V. ;

Drake, Charles G. .

CANCER IMMUNOLOGY AND IMMUNOTHERAPY, 2011, 344 :269-278

[18] Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival [J].

Griffiths, Richard W. ;

Elkord, Eyad ;

Gilham, David E. ;

Ramani, Vijay ;

Clarke, Noel ;

Stern, Peter L. ;

Hawkins, Robert E. .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2007, 56 (11) :1743-1753

[19] Improved Survival with Ipilimumab in Patients with Metastatic Melanoma [J].

Hodi, F. Stephen ;

O'Day, Steven J. ;

McDermott, David F. ;

Weber, Robert W. ;

Sosman, Jeffrey A. ;

Haanen, John B. ;

Gonzalez, Rene ;

Robert, Caroline ;

Schadendorf, Dirk ;

Hassel, Jessica C. ;

Akerley, Wallace ;

van den Eertwegh, Alfons J. M. ;

Lutzky, Jose ;

Lorigan, Paul ;

Vaubel, Julia M. ;

Linette, Gerald P. ;

Hogg, David ;

Ottensmeier, Christian H. ;

Lebbe, Celeste ;

Peschel, Christian ;

Quirt, Ian ;

Clark, Joseph I. ;

Wolchok, Jedd D. ;

Weber, Jeffrey S. ;

Tian, Jason ;

Yellin, Michael J. ;

Nichol, Geoffrey M. ;

Hoos, Axel ;

Urba, Walter J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (08) :711-723

[20] Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma [J].

Hudes, Gary ;

Carducci, Michael ;

Tomczak, Piotr ;

Dutcher, Janice ;

Figlin, Robert ;

Kapoor, Anil ;

Staroslawska, Elzbieta ;

Sosman, Jeffrey ;

McDermott, David ;

Bodrogi, Istvan ;

Kovacevic, Zoran ;

Lesovoy, Vladimir ;

Schmidt-Wolf, Ingo G. H. ;

Barbarash, Olga ;

Gokmen, Erhan ;

O'Toole, Timothy ;

Lustgarten, Stephanie ;

Moore, Laurence ;

Motzer, Robert J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (22) :2271-2281

← 1 2 3 4 5 6 7 →